BiotechTube

Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchiectasis

Conditions

Bronchiectasis

Trial Timeline

Apr 30, 2014 → Oct 19, 2016

NCT ID
NCT02106832

About Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo

Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo is a phase 3 stage product being developed by Novartis for Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02106832. Target conditions include Bronchiectasis.

What happened to similar drugs?

1 of 9 similar drugs in Bronchiectasis were approved

Approved (1) Terminated (2) Active (7)
✅Aztreonam lysineGilead SciencesApproved
❌Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
🔄Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
🔄AZLI + PlaceboGilead SciencesPhase 3
🔄AZLI + PlaceboGilead SciencesPhase 3
🔄HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
🔄Brensocatib 10 mg + Brensocatib 25 mg + PlaceboInsmedPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02106832Phase 3Completed

Competing Products

20 competing products in Bronchiectasis

See all competitors
ProductCompanyStageHype Score
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
32
AZD9668 + PlaceboAstraZenecaPhase 2
35
AZD5069 + PlaceboAstraZenecaPhase 2
35
AZD0292AstraZenecaPhase 2
42
TIP + TIP and placebo + PlaceboNovartisPhase 2
35
Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
40
Placebo to Ciprofloxacin DPI (BAYQ3939)NovartisPre-clinical
26
QBW251 + PlaceboNovartisPhase 2
27
Ciprofloxacin (Cipro, BAYQ3939) + PlaceboNovartisPhase 2
35
AZLI + PlaceboGilead SciencesPhase 3
40
Aztreonam lysineGilead SciencesApproved
35
AZLIGilead SciencesPhase 2
35
AZLI + PlaceboGilead SciencesPhase 3
40
Itepekimab (SAR440340) + PlaceboSanofiPhase 2
35
CSL787 + PlaceboCSLPhase 1
29
CSL787 + PlaceboCSLPhase 2
42
HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
47
HSK31858 + placeboHaisco Pharmaceutical GroupPhase 2
35
Group A + Group BBayerPre-clinical
23
BAY85-8501 + PlaceboBayerPhase 2
32